New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

What factors do you take into account for recommending venetoclax/obtinutuzumab vs BTK inhibitors vs chemotherapy in front line therapy for CLL?

1
5 Answers

Mednet MemberInvited Expert
Medical Oncology · Ohio State University

For most patients, either BTK inhibitor or venetoclax/obinutuzumab would be appropriate therapies. I would only consider chemotherapy (fludarabine/cyclophosphamide/rituximab) for those <65 years old with IGHV mutated disease and no high risk genetic markers. And even in these patients, I almost alwa...

For CLL patients with high-risk cytogenetics on ibrutinib who develop a cardiac event such as an MI, would you continue ibrutinib?

3
5 Answers

Mednet MemberInvited Expert
Medical Oncology · UC Irvine

It depends on the cardiac event (and the CLL status). After any serious event, if the CLL is under good control (clinical CR), I think it is very acceptable to stop the ibrutinib and wait until clinical progression occurs - which can be a while for some patients (median 2 years from the E1912 study)...

Would you ever consider using ibrutinib in CLL patients who have received first line acalabrutinib and then progressed?

3 Answers

Mednet MemberInvited Expert
Medical Oncology · City of Hope

There is no benefit of switching between covalent BTKi (Acalabrutinib, zanubrutinib, or ibrutinib) especially in CLL which, in most cases, is driven by a C481S which renders all three ineffective. The only rationale situation to switch between the three would be intolerance. In this situation, switc...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

How do you approach treatment for a fit patient with unmutated CLL who has progressed after BTKi and venetoclax containing regimens in the first and second line?

2
3 Answers

Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center

Original answer: February 10, 2023 This is a tough situation and we are seeing increasing number of patients who have failed both BTKi and BCL2i. Clinical trial enrollment with non covalent BTKi, or other novel strategies including CAR T cell therapy should be considered. PI3K inhibitors are also ap...

Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?

1
1 Answers

Mednet MemberInvited Expert
Medical Oncology · UPMC Hillman Cancer Center

In this patient, the finding of a TP53 mutation trumps all, including complex karyotype. In the absence of TP53 mutation or deletion of 17p13.1 (the TP53 locus) on FISH, complex karyotype of 5 or greater abnormalities is generally associated with shorter time to treatment and PFS on both chemoimmuno...

How do CLL patients with downstream treatment-resistant mutations such as PLCG2 respond to pirtobrutinib?

4 Answers

Mednet MemberInvited Expert
Medical Oncology · Lewisburg Cancer Center | Evangelical Hospital

Although BTK/PLCG2 mutations are present in patients with CLL relapsing on covalent BTK inhibitors, more than one-third of them DO NOT harbor such mutations even after high-sensitivity analyses. Additional genetic mechanisms, in particular aberrant activation of the BcR and NF-κB pathways, may be re...

Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?

2 Answers

Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center

Not really. I generally start pirtobrutinib at the standard dose of 200 mg daily.

Would you consider IV thrombolytics in patients with acute ischemic stroke, with or without a large vessel occlusion, if they have a history of von Willebrand disease (VWD), regardless of its type?

1 Answers

Mednet Member
Neurology · Methodist Hospital

I would still consider it unless the INR >1.7 or they are on anticoagulation for some clinical reason.

How do you treat patients with T-cell ALL/T-cell lymphoblastic lymphoma who have pre-existing CKD with a CrCl of 30 mL/min or less?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · University of Washington

In our experience, it requires very close coordination with our clinical pharmacists to ensure proper dose adjustments are made. By doing this, you will hopefully deliver comparable dose intensity without increased toxicity. This assumes you achieve the same level of drug exposure for the agents tha...

Can a patient still have primary HLH even in the absence of any HLH associated genetic mutations?

1
1 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Kapiolani Medical Center for Women & Children

Yes, a patient can still have primary Hemophagocytic Lymphohistiocytosis (HLH) even in the absence of identified HLH-associated genetic mutations.Primary HLH, also known as familial HLH, is typically linked to mutations in genes related to the immune system, such as PRF1, UNC13D, STX11, STXBP2, and ...